Hereditary Angioedema Treatments
Find Hereditary Angioedema Treatments
Medications for Hereditary Angioedema
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hereditary Angioedema.
Found 6 Approved Drugs for Hereditary Angioedema
Icatibant
Brand Names
Firazyr, Sajazir
Icatibant
Brand Names
Firazyr, Sajazir
Form: Injection
Method of administration: Subcutaneous
FDA approval date: August 25, 2011
Classification: Bradykinin B2 Receptor Antagonist
FIRAZYR ® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. FIRAZYR is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
Danazol
Generic Name
Danazol
Danazol
Generic Name
Danazol
Form: Capsule
Method of administration: Oral
FDA approval date: August 09, 1996
Classification: Androgen
Endometriosis. Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Hereditary Angioedema. Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.
Kalbitor
Generic Name
Ecallantide
Kalbitor
Generic Name
Ecallantide
Form: Injection
Method of administration: Subcutaneous
FDA approval date: February 02, 2010
Classification: Plasma Kallikrein Inhibitor
KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. KALBITOR is a plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. ( 1 )
Andembry
Generic Name
Garadacimab
Andembry
Generic Name
Garadacimab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 16, 2025
ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is an activated Factor XII (FXIIa) inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )
Ekterly
Generic Name
Sebetralstat
Ekterly
Generic Name
Sebetralstat
Form: Tablet
Method of administration: Oral
FDA approval date: July 03, 2025
Classification: Plasma Kallikrein Inhibitor
EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances